Voya Investment Management LLC boosted its position in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 12.8% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 27,747 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,157 shares during the period. Voya Investment Management LLC owned about 0.05% of SciClone Pharmaceuticals worth $305,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. State of Alaska Department of Revenue boosted its holdings in shares of SciClone Pharmaceuticals by 78.9% in the 2nd quarter. State of Alaska Department of Revenue now owns 10,213 shares of the specialty pharmaceutical company’s stock valued at $112,000 after purchasing an additional 4,503 shares during the last quarter. Profund Advisors LLC acquired a new position in shares of SciClone Pharmaceuticals in the 2nd quarter valued at $113,000. OppenheimerFunds Inc. boosted its holdings in shares of SciClone Pharmaceuticals by 29.9% in the 1st quarter. OppenheimerFunds Inc. now owns 13,309 shares of the specialty pharmaceutical company’s stock valued at $131,000 after purchasing an additional 3,065 shares during the last quarter. Kassirer Asset Management Corp acquired a new position in shares of SciClone Pharmaceuticals in the 2nd quarter valued at $165,000. Finally, BNP Paribas Arbitrage SA boosted its holdings in shares of SciClone Pharmaceuticals by 54.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 16,140 shares of the specialty pharmaceutical company’s stock valued at $178,000 after purchasing an additional 5,658 shares during the last quarter. 72.80% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/11/15/sciclone-pharmaceuticals-inc-scln-holdings-increased-by-voya-investment-management-llc.html.

SciClone Pharmaceuticals, Inc. (NASDAQ SCLN) opened at $11.15 on Wednesday. SciClone Pharmaceuticals, Inc. has a 1-year low of $8.55 and a 1-year high of $11.43.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.